Basilea Earns $5M Milestone from Pfizer’s Cresemba Sales in Asia Pacific
Event summary
- Basilea received a $5 million milestone payment from Pfizer due to strong Cresemba sales in Asia Pacific and China.
- Cresemba’s global sales grew 27% year-on-year to $693 million in the 12 months ending September 2025.
- The antifungal is approved in over 75 countries, including China, the EU, the UK, and the US.
- Basilea markets Cresemba alongside Zevtera for bacterial infections, with additional anti-infective assets in development.
The big picture
Basilea’s milestone underscores the growing demand for novel antifungals in high-growth markets like Asia Pacific. Cresemba’s 27% global sales growth positions it as the leading branded antifungal, but sustained performance hinges on Pfizer’s regional execution and Basilea’s ability to expand its anti-infective portfolio. The $5 million payment highlights the strategic value of licensing deals in scaling commercial-stage biopharmaceuticals.
What we're watching
- Regional Demand
- Whether Asia Pacific and China can sustain Cresemba’s growth trajectory amid rising antifungal resistance.
- Partnership Performance
- How Pfizer’s commercial execution will impact future milestone payments and royalty streams for Basilea.
- Pipeline Development
- The pace at which Basilea advances its preclinical and clinical anti-infective assets to diversify revenue.
Related topics